bsmbi v2 digested plenticrisprv2 (New England Biolabs)
New England Biolabs is a verified supplier 
New England Biolabs manufactures this product 
99
Structured Review
New England Biolabs
bsmbi v2 digested plenticrisprv2
Bsmbi V2 Digested Plenticrisprv2, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1655 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bsmbi+v2+digested+plenticrisprv2/BsmBI/bio_rxiv__64898__2026__03__11__711115-218-9-19
Average 99 stars, based on 1655 article reviews
Bsmbi V2 Digested Plenticrisprv2, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1655 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bsmbi+v2+digested+plenticrisprv2/BsmBI/bio_rxiv__64898__2026__03__11__711115-218-9-19
Average 99 stars, based on 1655 article reviews
bsmbi v2 digested plenticrisprv2 - by Bioz Stars,
2026-09
99/100 stars
Images
1) Product Images from "Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy"
Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy
Journal: bioRxiv
doi: 10.64898/2026.03.11.711115
Figure Legend Snippet: Data Supporting Figure 5. A , Immunoblot from lysates of A549 cells or SLC7A11 knockout clones for indicated proteins upon treatment with βMe (50μM). Inferred MW of band indicated. B , Viability (ATP) of cells from C cultured in the presence or absence of cystine (CySS) with indicated concentration of supplemented βMe for 3 days. Data report mean of technical triplicates. C , Viability (ATP) of A549 cells in cystine-free media or upon erastin treatment (10μM), or SLC7A11 knockout clones in standard conditions, treated with the indicated concentrations of reducing agents βMe, dithiothreitol (DTT), or Tris(2-carboxyethyl)phosphine (TCEP), 3 days. Data are the mean of two technical replicates. D , Viability (ATP, solid lines) and GSH content (dashed lines) of A549 cells cultured at indicated CySS concentration for 3 days. Data report mean of two technical replicates. E , Upper left, schematic delineating the contribution of serine-derived carbon to cysteine, glycine, GSH, or GSSG. Right, isotopic labeling of the indicated metabolites derived from A549 cells cultured in U- 13 C-serine (286 μM) as the only source of serine (top, GC-MS detection; bottom, LC-MS detection), in the presence or absence of CySS or βMe (50 μM) for 24 hr. ND = not detected. F , Crystal violet staining of A549 SLC7A11 knockout clones from upon transwell culture with A549 cells expressing pLentiCRISPRv2 or an SLC7A11 knockout clone, 3 days. Data are from one experiment. G , Immunoblot from lysates of A549 cells or SLC7A11 knockout clones for indicated proteins in the presence or absence of CySS, βMe (50 μM) of Fer-1 (10 μM) for 2 days. Inferred MW of band indicated. Data are from one experiment. H , Viability (ATP) of A549 cells upon treatment with Na2SeO3 and the indicated concentrations of reducing agents βMe, DTT, or TCEP, 3 days. Data are the mean ± SEM of n=3 biological replicates.
Techniques Used: Western Blot, Knock-Out, Clone Assay, Cell Culture, Concentration Assay, Derivative Assay, Isotopic Labeling, Gas Chromatography-Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Staining, Expressing
Related Articles
Purification:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Clone Assay:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Western Blot:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Knock-Out:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Cell Culture:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Concentration Assay:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Derivative Assay:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Isotopic Labeling:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Gas Chromatography-Mass Spectrometry:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Liquid Chromatography with Mass Spectroscopy:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Staining:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. Expressing:Article Title: Systematic Evaluation Defines the Limits of Ferroptosis in Cancer Therapy Article Snippet: Oligonucleotide pools were synthesized by Twist Bioscience. |